Effect of Shuganjianpifang on cardiac diastolic function and inflammatory factors in rats with nonalcoholic steatosis hepatitis
Wen-Jing Wang,Qin-He Yang,Gao-Fei Feng,Yan-Ping Wang,Xiu-Min He,Yu-Pei Zhang,Xue-Ping Yang,Hai-Zhen Yan,Jin Huang,Guang-Qiu Li,Ya-Feng Zhao,Xiao-Lei Yang,Can-Hong Shen
2011-01-01
World Chinese Journal of Digestology
Abstract:AIM: To investigate the effect of Shuganjianpifang on cardiac diastolic dysfunction in rats with nonalcoholic steatosis hepatitis (NASH) and to explore the possible mechanisms involved. METHODS: NASH was induced in rats by feeding a high-fat diet. Rats were divided into eight groups: normal control group, model group, high- and low-dose Ganfang, Pifang and Shuganjianpifang groups. After treatment for 16 weeks, stroke volume (SV), left ventricular ejection fraction (LVEF), and left ventricular diameter (LVFS) were measured to evaluate cardiac systolic function, and E/A ratio was calculated to evaluate cardiac diastolic function. Serum levels of TC, TG, HDL, and LDL, as well as TC and TG in the hepatic homogenate were detected using an automatic biochemical analyzer. Histopathological changes were observed after HE staining. Serum TNF-α and IL-6 levels were determined by enzyme-linked immunosorbent assay (ELISA). RESULTS: Compared to the normal group, rats in the model group revealed medium fatty degeneration in hepatocytes, declined cardiac diastolic function (1.59 ± 0.24 vs 1.03 ± 0.13, P < 0.01), increased serum levels TNF-α (13.57 ± 4.64 vs 28.26 ± 8.60, P < 0.01), IL-6 (59.28 ± 71.53 vs 132.81 ± 74.22, P < 0.05), TC (1.42 ± 0.29 vs 3.82 ± 0.91, P < 0.01), LDL (0.30 ± 0.11 vs 0.81 ± 0.27, P < 0.01) and hepatic levels of TC (0.90 ± 0.14 vs 11.86 ± 1.29, P < 0.01) and TG (0.75 ± 0.38 vs 6.17 ± 1.83, P < 0.01), and decreased SV, LVEF and LVFS in the model group. Compared to the model group, cardiac diastolic function was significantly improved in rats in each treatment group, especially prominent in the high-dose Shuganjianpifang group (1.26 ± 0.23 vs 1.03 ± 0.13; 1.35 ± 0.15 vs 1.03 ± 0.13, both P < 0.01). In addition, the levels of blood and liver lipids and serum TNF-α and IL-6 decreased in each treatment group, especially in the high-dose Shuganjianpifang group (0.45 ± 0.14 vs 0.83 ± 0.26; 9.17 ± 1.02 vs 11.86 ± 1.29; 2.54 ± 0.74 vs 6.17 ± 1.83; 15.07 ± 6.00 vs 28.26 ± 8.60; 67.72 ± 44.24 vs 132.81 ± 74.22, all P < 0.01). CONCLUSION: Rats with NASH develop cardiac diastolic dysfunction. Shuganjianpifang could improve cardiac diastolic function possibly by decreasing serum levels of TNF-α and IL-6 in rats with NASH.